Addiction - Pipeline Review, H2 2012


#156146

362pages

Global Markets Direct

$ 2000

In Stock


Global Markets Directs, 'Addiction Pipeline Review, H2 2012', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Addiction, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Addiction. 

Addiction Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Addiction.
  • A review of the Addiction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Addiction pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.
Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Addiction.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Addiction pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2
List of Tables 20
List of Figures 22

Introduction 23
Global Markets Direct Report Coverage 23
Addiction Overview 24
Therapeutics Development 25
An Overview of Pipeline Products for Addiction 25
Addiction Therapeutics under Development by Companies 27
Addiction Therapeutics under Investigation by Universities/Institutes 32
Late Stage Products 37
Comparative Analysis 37
Mid Clinical Stage Products 38
Comparative Analysis 38
Early Clinical Stage Products 39
Comparative Analysis 39
Discovery and Pre-Clinical Stage Products 40
Comparative Analysis 40
Addiction Therapeutics - Products under Development by Companies 41
Addiction Therapeutics - Products under Investigation by Universities/Institutes 45
Companies Involved in Addiction Therapeutics Development 53
Abbott Laboratories 53
Aradigm Corporation 54
Tekmira Pharmaceuticals Corp. 55
Alkermes, Inc. 56
Nanotherapeutics, Inc. 57
Nabi Biopharmaceuticals 58
Novartis AG 59
EnVivo Pharmaceuticals 60
Mitsubishi Tanabe Pharma Corporation 61
Nippon Shinyaku Co., Ltd. 62
Pfizer Inc. 63
Sun Pharmaceutical Industries Limited 64
Addex Pharmaceuticals 65
AEterna Zentaris Inc. 66
Catalyst Pharmaceutical Partners, Inc. 67
Mundipharma International Limited 68
Titan Pharmaceuticals, Inc. 69
Biotie Therapies Corp. 70
Orexo AB 71
Mount Sinai School of Medicine 72
Camurus AB 73
Global Health Ventures Inc. 74
Omeros Corporation 75
ImmunoVaccine Technologies Inc. 76
Targacept, Inc. 77
Cary Pharmaceuticals Inc. 78
CBio Limited 79
Vanda Pharmaceuticals Inc. 80
KYORIN Pharmaceutical Co., Ltd. 81
Royalty Pharma 82
Sihuan Pharmaceutical Holdings Group Ltd. 83
Selecta Biosciences, Inc. 84
Heptares Therapeutics Ltd. 85
Envoy Therapeutics, Inc. 86
Embera NeuroTherapeutics, Inc. 87
Lightlake Therapeutics Inc. 88
TheraQuest Biosciences, LLC 89
Celtic Pharmaceutical Holdings L.P. 90
Beech Tree Labs, Inc. 91
Naurex, Inc. 92
22nd Century Limited, LLC 93
Addiction - Therapeutics Assessment 94
Assessment by Monotherapy Products 94
Assessment by Combination Products 95
Assessment by Route of Administration 96
Assessment by Molecule Type 99
Drug Profiles 102
nepicastat hydrochloride - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
nalmefene - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
GW-468816 - Drug Profile 105
Product Description 105
Mechanism of Action 105
R&D Progress 105
NicVAX - Drug Profile 107
Product Description 107
Mechanism of Action 107
R&D Progress 107
NIC-002 - Drug Profile 109
Product Description 109
Mechanism of Action 109
R&D Progress 109
acamprosate calcium - Drug Profile 130
Product Description 130
Mechanism of Action 130
R&D Progress 130
Oxazepam + Metyrapone - Drug Profile 131
Product Description 131
Mechanism of Action 131
R&D Progress 131
lofexidine hydrochloride - Drug Profile 133
Product Description 133
Mechanism of Action 133
R&D Progress 133
Lofexidine + Marinol - Drug Profile 134
Product Description 134
Mechanism of Action 134
R&D Progress 134
CPP-115 - Drug Profile 135
Product Description 135
Mechanism of Action 135
R&D Progress 135
varenicline tartrate - Drug Profile 148
Product Description 148
Mechanism of Action 148
R&D Progress 148
naltrexone - Drug Profile 149
Product Description 149
Mechanism of Action 149
R&D Progress 149
biperiden - Drug Profile 151
Product Description 151
Mechanism of Action 151
R&D Progress 151
nabilone - Drug Profile 152
Product Description 152
Mechanism of Action 152
R&D Progress 152
buprenorphine hydrochloride - Drug Profile 153
Product Description 153
Mechanism of Action 153
R&D Progress 153
bupropion hydrochloride - Drug Profile 154
Product Description 154
Mechanism of Action 154
R&D Progress 154
varenicline tartrate - Drug Profile 155
Product Description 155
Mechanism of Action 155
R&D Progress 155
Chantix + Bupropion - Drug Profile 156
Product Description 156
Mechanism of Action 156
R&D Progress 156
varenicline tartrate - Drug Profile 208
Product Description 208
Mechanism of Action 208
R&D Progress 208
TA-NIC - Drug Profile 209
Product Description 209
Mechanism of Action 209
R&D Progress 209
samidorphan + buprenorphine hydrochloride - Drug Profile 211
Product Description 211
Mechanism of Action 211
R&D Progress 211
propranolol hydrochloride - Drug Profile 213
Product Description 213
Mechanism of Action 213
R&D Progress 213
baclofen - Drug Profile 215
Product Description 215
Mechanism of Action 215
R&D Progress 215
Nicotine Patch + Bupropion SR - Drug Profile 216
Product Description 216
Mechanism of Action 216
R&D Progress 216
vigabatrin - Drug Profile 262
Product Description 262
Mechanism of Action 262
R&D Progress 262
nicotine - Drug Profile 263
Product Description 263
Mechanism of Action 263
R&D Progress 263
nabilone - Drug Profile 264
Product Description 264
Mechanism of Action 264
R&D Progress 264
nicotine - Drug Profile 265
Product Description 265
Mechanism of Action 265
R&D Progress 265
NMDAR modulators - Drug Profile 266
Product Description 266
Mechanism of Action 266
R&D Progress 266
OND-PR002 + Ritalin - Drug Profile 267
Product Description 267
Mechanism of Action 267
R&D Progress 267
varenicline tartrate - Drug Profile 309
Product Description 309
Mechanism of Action 309
R&D Progress 309
Addiction Therapeutics - Drug Profile Updates 310
Addiction Therapeutics - Discontinued Products 339
Addiction Therapeutics - Dormant Products 341
Addiction - Product Development Milestones 353
Featured News & Press Releases 353
Nov 20, 2012: MediciNova Initiates Phase IIa Trial Of MN-166 In Opioid Abusers 353
Nov 19, 2012: Orexo Announces FDA's Accepatance To Review Zubsolv 354
Nov 08, 2012: Catalyst Pharma Announces Top-Line Results Of CPP-109 Phase IIb Trial For Cocaine Addiction 354
Nov 08, 2012: Catalyst Pharma Announces Top-Line Results Of CPP-109 Phase IIb Trial For Cocaine Addiction 355
Oct 29, 2012: Addex Therapeutics Announces Positive Preclinical Data For ADX71441 For Treatment Of Alcoholism 355
Oct 29, 2012: Titan Pharma Submits New Drug Application For Probuphine For Treatment Of Opioid Dependence 356
Oct 17, 2012: Nabi Biopharma's Phase II Study Of NicVAX In Combination With Varenicline Does Not Meet Primary Endpoint 357
Oct 16, 2012: Pfizer Completes Efficacy And Safety Study Of Smoking Cessation Drug Chantix 358
Oct 10, 2012: Perrigo Receives FDA Approval To Market Mini Nicotine Lozenges 359
Sep 26, 2012: Catalyst Pharma Provides Update On Timing Of Top-Line Data From Phase IIb Cocaine Addiction Study 359

Appendix 361
Methodology 361
Coverage 361
Secondary Research 361
Primary Research 361
Expert Panel Validation 361
Contact Us 362
Disclaimer 362

Number of Products Under Development for Addiction, H2 2012 25
Products under Development for Addiction - Comparative Analysis, H2 2012 26
Number of Products under Development by Companies, H2 2012 28
Number of Products under Development by Companies, H2 2012 (Contd..1) 29
Number of Products under Development by Companies, H2 2012 (Contd..2) 30
Number of Products under Development by Companies, H2 2012 (Contd..3) 31
Number of Products under Investigation by Universities/Institutes, H2 2012 33
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 34
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 35
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 36
Comparative Analysis by Late Stage Development, H2 2012 37
Comparative Analysis by Mid Clinical Stage Development, H2 2012 38
Comparative Analysis by Early Clinical Stage Development, H2 2012 39
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 40
Products under Development by Companies, H2 2012 41
Products under Development by Companies, H2 2012 (Contd..1) 42
Products under Development by Companies, H2 2012 (Contd..2) 43
Products under Development by Companies, H2 2012 (Contd..3) 44
Products under Investigation by Universities/Institutes, H2 2012 45
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 46
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 47
Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 48
Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 49
Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 50
Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 51
Products under Investigation by Universities/Institutes, H2 2012 (Contd..7) 52
Abbott Laboratories, H2 2012 53
Aradigm Corporation, H2 2012 54
Tekmira Pharmaceuticals Corp., H2 2012 55
Alkermes, Inc., H2 2012 56
Nanotherapeutics, Inc., H2 2012 57
Nabi Biopharmaceuticals, H2 2012 58
Novartis AG, H2 2012 59
EnVivo Pharmaceuticals, H2 2012 60
Mitsubishi Tanabe Pharma Corporation, H2 2012 61
Nippon Shinyaku Co., Ltd., H2 2012 62
Pfizer Inc., H2 2012 63
Sun Pharmaceutical Industries Limited, H2 2012 64
Addex Pharmaceuticals, H2 2012 65
AEterna Zentaris Inc., H2 2012 66
Catalyst Pharmaceutical Partners, Inc., H2 2012 67
Mundipharma International Limited, H2 2012 68
Titan Pharmaceuticals, Inc., H2 2012 69
Biotie Therapies Corp., H2 2012 70
Orexo AB, H2 2012 71
Mount Sinai School of Medicine, H2 2012 72
Camurus AB, H2 2012 73
Global Health Ventures Inc., H2 2012 74
Omeros Corporation, H2 2012 75
ImmunoVaccine Technologies Inc., H2 2012 76
Targacept, Inc., H2 2012 77
Cary Pharmaceuticals Inc., H2 2012 78
CBio Limited, H2 2012 79
Vanda Pharmaceuticals Inc., H2 2012 80
KYORIN Pharmaceutical Co., Ltd., H2 2012 81
Royalty Pharma, H2 2012 82
Sihuan Pharmaceutical Holdings Group Ltd., H2 2012 83
Selecta Biosciences, Inc., H2 2012 84
Heptares Therapeutics Ltd., H2 2012 85
Envoy Therapeutics, Inc., H2 2012 86
Embera NeuroTherapeutics, Inc., H2 2012 87
Lightlake Therapeutics Inc., H2 2012 88
TheraQuest Biosciences, LLC, H2 2012 89
Celtic Pharmaceutical Holdings L.P., H2 2012 90
Beech Tree Labs, Inc., H2 2012 91
Naurex, Inc., H2 2012 92
22nd Century Limited, LLC, H2 2012 93
Assessment by Monotherapy Products, H2 2012 94
Assessment by Combination Products, H2 2012 95
Assessment by Stage and Route of Administration, H2 2012 98
Assessment by Stage and Molecule Type, H2 2012 101
Addiction Therapeutics - Drug Profile Updates 310
Addiction Therapeutics - Discontinued Products 339
Addiction Therapeutics - Discontinued Products (Contd..1) 340
Addiction Therapeutics - Dormant Products 341
Addiction Therapeutics - Dormant Products (Contd..1) 342
Addiction Therapeutics - Dormant Products (Contd..2) 343
Addiction Therapeutics - Dormant Products (Contd..3) 344
Addiction Therapeutics - Dormant Products (Contd..4) 345
Addiction Therapeutics - Dormant Products (Contd..5) 346
Addiction Therapeutics - Dormant Products (Contd..6) 347
Addiction Therapeutics - Dormant Products (Contd..7) 348
Addiction Therapeutics - Dormant Products (Contd..8) 349
Addiction Therapeutics - Dormant Products (Contd..9) 350
Addiction Therapeutics - Dormant Products (Contd..10) 351
Addiction Therapeutics - Dormant Products (Contd..11) 352
Number of Products under Development for Addiction, H2 2012 25
Products under Development for Addiction - Comparative Analysis, H2 2012 26
Products under Development by Companies, H2 2012 27
Products under Investigation by Universities/Institutes, H2 2012 32
Late Stage Products, H2 2012 37
Mid Clinical Stage Products, H2 2012 38
Early Clinical Stage Products, H2 2012 39
Discovery and Pre-Clinical Stage Products, H2 2012 40
Assessment by Monotherapy Products, H2 2012 94
Assessment by Combination Products, H2 2012 95
Assessment by Route of Administration, H2 2012 96
Assessment by Stage and Route of Administration, H2 2012 97
Assessment by Molecule Type, H2 2012 99
Assessment by Stage and Molecule Type, H2 2012 100